{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T23:02:55Z","timestamp":1775084575424,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003107","name":"German Federal Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003107","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reproductive Toxicology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.reprotox.2023.108415","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T21:01:44Z","timestamp":1685134904000},"page":"108415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Prescribing of endothelin receptor antagonists and riociguat in women of childbearing age in a large German claims database study"],"prefix":"10.1016","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5913-6031","authenticated-orcid":false,"given":"Ute","family":"Amann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Nadine Wentzell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Kollhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Haug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.reprotox.2023.108415_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.reprotox.2023.108415_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12055","article-title":"Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat","volume":"12","author":"Rahaghi","year":"2022","journal-title":"Pulm. Circ."},{"issue":"162","key":"10.1016\/j.reprotox.2023.108415_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0330-2020","article-title":"Sex and gender in pulmonary arterial hypertension","volume":"30","author":"Cheron","year":"2021","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.reprotox.2023.108415_bib4","unstructured":"European Medicines Agency. European public assessment report (EPAR): Adempas (riociguat). Product information (first published 2014, last updated 2022). \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/adempas#product-information-section\u3009 [last accessed on 04 January 2023]."},{"key":"10.1016\/j.reprotox.2023.108415_bib5","unstructured":"European Medicines Agency. EPAR: Opsumit (macitentan). Product information (first published 2014, last updated 2022). \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/opsumit#product-information-section\u3009 [last accessed on 04 January 2023]."},{"key":"10.1016\/j.reprotox.2023.108415_bib6","unstructured":"European Medicines Agency. EPAR: Volibris (ambrisentan). Product information (first published 2010, last updated 2021). \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/volibris#product-information-section\u3009 [last accessed on 04 January 2023]."},{"key":"10.1016\/j.reprotox.2023.108415_bib7","unstructured":"European Medicines Agency. EPAR: Tracleer (bosentan). Product information (first published 2009, last updated 2019). \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tracleer#product-information-section\u3009 [last accessed on 04 January 2023]."},{"issue":"2","key":"10.1016\/j.reprotox.2023.108415_bib8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/bcpt.13033","article-title":"A focus on macitentan in the treatment of pulmonary arterial hypertension","volume":"123","author":"Bedan","year":"2018","journal-title":"Basic Clin. Pharm. Toxicol."},{"issue":"5","key":"10.1016\/j.reprotox.2023.108415_bib9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/bdrb.21021","article-title":"An evaluation of reproductive and developmental toxicity of sitaxentan (thelin) in rats","volume":"95","author":"Cross","year":"2012","journal-title":"Birth Defects Res B Dev. Reprod. Toxicol."},{"key":"10.1016\/j.reprotox.2023.108415_bib10","unstructured":"European Medicines Agency. EPAR: Tracleer\/Stayveer (bosentan). Risk-management-plan summary 2019. \u3008https:\/\/www.ema.europa.eu\/documents\/rmp-summary\/tracleer-epar-risk-management-plan-summary_en.pdf\u3009 [last accessed on 04 January 2023]."},{"key":"10.1016\/j.reprotox.2023.108415_bib11","unstructured":"European Medicines Agency. EPAR: Volibris (ambrisentan). Risk-management-plan summary (first published 2019, last updated 2021). \u3008https:\/\/www.ema.europa.eu\/documents\/rmp-summary\/volibris-epar-risk-management-plan-summary_en.pdf\u3009 [last accessed on 04 January 2023]."},{"key":"10.1016\/j.reprotox.2023.108415_bib12","unstructured":"European Medicines Agency. EPAR: Opsumit (macitentan). Risk-management-plan summary. \u3008https:\/\/www.ema.europa.eu\/documents\/rmp-summary\/opsumit-epar-risk-management-plan-summary_en.pdf\u3009 (first published 2020, last updated 2022) [last accessed on 04 January 2023]."},{"key":"10.1016\/j.reprotox.2023.108415_bib13","unstructured":"European Medicines Agency. EPAR: Adempas (riociguat). Risk-management-plan summary 2014. \u3008https:\/\/www.ema.europa.eu\/documents\/rmp-summary\/adempas-epar-risk-management-plan-summary_en.pdf\u3009 [last accessed on 04 January 2023]."},{"issue":"5","key":"10.1016\/j.reprotox.2023.108415_bib14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/0018578718791509","article-title":"A retrospective analysis of adherence to risk evaluation and mitigation strategies requirements for pulmonary arterial hypertension drugs","volume":"54","author":"Prokes","year":"2019","journal-title":"Hosp. Pharm."},{"issue":"3","key":"10.1016\/j.reprotox.2023.108415_bib15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.healun.2020.12.002","article-title":"Pregnancy in pulmonary arterial hypertension: Midterm outcomes of mothers and offspring","volume":"40","author":"Kamp","year":"2021","journal-title":"J. Heart Lung Transpl."},{"issue":"25 Suppl","key":"10.1016\/j.reprotox.2023.108415_bib16","doi-asserted-by":"crossref","first-page":"D51","DOI":"10.1016\/j.jacc.2013.10.023","article-title":"Pulmonary arterial hypertension: epidemiology and registries","volume":"62","author":"McGoon","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.reprotox.2023.108415_bib17","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024969","article-title":"Mortality in pulmonary arterial hypertension in the modern era: Early insights from the Pulmonary Hypertension Association Registry","volume":"11","author":"Chang","year":"2022","journal-title":"J. Am. Heart Assoc."},{"issue":"6","key":"10.1016\/j.reprotox.2023.108415_bib18","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01552-2021","article-title":"Mortality trends in pulmonary arterial hypertension in Canada: A temporal analysis of survival per ESC\/ERS guideline era","volume":"59","author":"Zelt","year":"2022","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.reprotox.2023.108415_bib19","unstructured":"Leibniz Institute for Prevention Research and Epidemiology - BIPS, The German Pharmacoepidemiological Research Database (GePaRD), 2020. \u3008https:\/\/www.bips-institut.de\/en\/research\/research-infrastructures\/gepard.html\u3009 (last accessed on 04 January 2023)."},{"key":"10.1016\/j.reprotox.2023.108415_bib20","series-title":"Databases for Pharmacoepidemiological Research","first-page":"119","article-title":"German Pharmacoepidemiological Research Database (GePaRD)","author":"Haug","year":"2020"},{"issue":"8","key":"10.1016\/j.reprotox.2023.108415_bib21","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/pds.3467","article-title":"Evaluation of pregnancy outcome records in the German Pharmacoepidemiological Research Database (GePaRD)","volume":"22","author":"Mikolajczyk","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"9","key":"10.1016\/j.reprotox.2023.108415_bib22","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/pds.4588","article-title":"Optimizing an algorithm for the identification and classification of pregnancy outcomes in German claims data","volume":"27","author":"Wentzell","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.reprotox.2023.108415_bib23","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3389\/fpubh.2020.00350","article-title":"Estimating the beginning of pregnancy in German claims data: Development of an algorithm with a focus on the expected delivery date","volume":"8","author":"Schink","year":"2020","journal-title":"Front Public Health"},{"issue":"3","key":"10.1016\/j.reprotox.2023.108415_bib24","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/pds.2038","article-title":"Linkage of mother-baby pairs in the German Pharmacoepidemiological Research Database","volume":"20","author":"Garbe","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.reprotox.2023.108415_bib25","unstructured":"EUROCAT. EUROCAT Guide 1.4 and reference documents. 2018 [updated 12\/28\/2018. \u3008https:\/\/eu-rd-platform.jrc.ec.europa.eu\/sites\/default\/files\/Full_Guide_1_4_version_28_DEC2018.pdf\u3009 (last accessed on 04 January 2023)."},{"issue":"4","key":"10.1016\/j.reprotox.2023.108415_bib26","first-page":"476","article-title":"Pregnancy in congenital heart disease, complicated by pulmonary arterial hypertension-a challenging issue for the pregnant woman, the foetus, and healthcare professionals","volume":"58","author":"Rudien\u0117","year":"2022","journal-title":"Med. (Kaunas. )"},{"key":"10.1016\/j.reprotox.2023.108415_bib27","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Norwegian Institute of Public Health. ATC\/DDD Index: C02KX Antihypertensives for pulmonary arterial hypertension. \u3008https:\/\/www.whocc.no\/atc_ddd_index\u3009 [last updated 19 Dec 2022, last accessed on 04 January 2023]."},{"issue":"38","key":"10.1016\/j.reprotox.2023.108415_bib28","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.reprotox.2023.108415_bib29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.reprotox.2015.06.048","article-title":"Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension","volume":"56","author":"de Raaf","year":"2015","journal-title":"Reprod. Toxicol."},{"issue":"4","key":"10.1016\/j.reprotox.2023.108415_bib30","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1183\/09031936.00141211","article-title":"Pregnancy outcomes in pulmonary arterial hypertension in the modern management era","volume":"40","author":"Ja\u00efs","year":"2012","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.reprotox.2023.108415_bib31","unstructured":"Haug U. [Prescribing of teratogenic drugs to women of childbearing age in Germany]. Bulletin zur Arzneimittelsicherheit 2020 [issue 4, December 2020, \u3008https:\/\/www.bfarm.de\/DE\/Aktuelles\/Publikationen\/Bulletin\/Ausgaben\/Bulletin-Archiv.html?nn=920546]\u3009 (last accessed on 04 January 2023)."},{"issue":"2","key":"10.1016\/j.reprotox.2023.108415_bib32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40261-022-01227-6","article-title":"Use of methotrexate in girls and women of childbearing age, occurrence of methotrexate-exposed pregnancies and their outcomes in Germany: a claims data analysis","volume":"43","author":"Wentzell","year":"2023","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.reprotox.2023.108415_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104184","article-title":"Fingolimod, teriflunomide and cladribine for the treatment of multiple sclerosis in women of childbearing age: description of drug utilization and exposed pregnancies in Germany","volume":"67","author":"Platzbecker","year":"2022","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Reproductive Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890623823000898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890623823000898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:02:19Z","timestamp":1760191339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890623823000898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":33,"alternative-id":["S0890623823000898"],"URL":"https:\/\/doi.org\/10.1016\/j.reprotox.2023.108415","relation":{},"ISSN":["0890-6238"],"issn-type":[{"value":"0890-6238","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prescribing of endothelin receptor antagonists and riociguat in women of childbearing age in a large German claims database study","name":"articletitle","label":"Article Title"},{"value":"Reproductive Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reprotox.2023.108415","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108415"}}